The FTC's Stance On Generic Biologics

Law360, New York (July 9, 2009, 12:00 AM EDT) -- This year marks the 25th anniversary of the Hatch-Waxman Act in the United States, which created a pathway for generic drugs by means of an abbreviated version of a New Drug Application for small molecule drugs regulated by the Federal Food, Drug and Cosmetic Act.

However, no pathway currently exists in the United States for generic biologics, or "follow-on biologics" ("FOBs"), by means of an abbreviated version of a Biologics License Application ("BLA") for larger and more complex biological molecules regulated by the Public Health Service...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.